StockNews.com lowered shares of OraSure Technologies (NASDAQ:OSUR – Free Report) from a buy rating to a hold rating in a research report released on Saturday.
OraSure Technologies Stock Up 5.0 %
NASDAQ:OSUR opened at $3.99 on Friday. The company has a fifty day moving average of $3.80 and a 200-day moving average of $4.02. The firm has a market capitalization of $297.63 million, a P/E ratio of 26.60 and a beta of 0.05. OraSure Technologies has a twelve month low of $3.52 and a twelve month high of $8.04.
Institutional Trading of OraSure Technologies
Hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC increased its stake in shares of OraSure Technologies by 202.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,821 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 5,234 shares in the last quarter. Causeway Capital Management LLC bought a new stake in shares of OraSure Technologies in the 4th quarter valued at $36,000. Raymond James Financial Inc. bought a new stake in OraSure Technologies during the 4th quarter valued at $37,000. Atom Investors LP bought a new stake in OraSure Technologies during the 3rd quarter valued at $49,000. Finally, Boothbay Fund Management LLC bought a new stake in OraSure Technologies during the 4th quarter valued at $42,000. Institutional investors own 93.50% of the company’s stock.
About OraSure Technologies
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
See Also
- Five stocks we like better than OraSure Technologies
- Overbought Stocks Explained: Should You Trade Them?
- Finding Hidden Gems: Unconventional Penny Stock Investing
- Using the MarketBeat Dividend Yield Calculator
- Price Targets on NVIDIA Rise in Front of Earnings
- What is the Australian Securities Exchange (ASX)
- Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
